US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating yesterday.Don't Miss our ...

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...